Table 3.
Percentage of variance accounted for | R = 0.436, R2 = 0.190, P < 0.001 | ||
---|---|---|---|
| |||
Significant predictors in the final regression model | β | β (95% CI) | P |
Intercept | −5.116 | −8.279, −1.954 | 0.002 |
Sex (male = 0, female = 1) | −0.913 | −1.735, −0.091 | 0.030 |
Solitary living at the respective assessment (no = 0, yes = 1) | 2.808 | 2.001, 3.616 | <0.001 |
ChEI dosea | −0.021 | −0.039, −0.002 | 0.030 |
Time in months from the start of ChEI therapy | 0.032 | 0.001, 0.062 | 0.041 |
MMSE score at the respective assessment | 0.133 | 0.060, 0.205 | <0.001 |
IADL score at the respective assessment | 0.305 | 0.199, 0.412 | <0.001 |
PSMS score at the respective assessment | 0.343 | 0.213, 0.474 | <0.001 |
Number of medications at baseline | −0.247 | −0.372, −0.121 | <0.001 |
Notes: APOE genotype, type of ChEI agent, age at onset or at baseline, years of education, rate of change in MMSE, IADL, or PSMS scores, and the interaction term “sex × solitary living” were not significant. β values were unstandardized and are expressed per 1 unit increase for continuous variables and for the condition present for dichotomous variables.
Mean percentage of the maximum recommended dose, ie, 10 mg of donepezil, 12 mg of rivastigmine, or 24 mg of galantamine.
Abbreviations: APOE, apolipoprotein E; ChEI, cholinesterase inhibitors; CI, confidence interval; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.